Bicycle Therapeutics plc (BCYC)

Market Cap	1.01B
Revenue (ttm)	36.90M
Net Income (ttm)	-166.28M
Shares Out	69.05M
EPS (ttm)	-3.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	290,849
Open	15.00
Previous Close	15.00
Day's Range	14.64 - 15.30
52-Week Range	12.17 - 28.67
Beta	0.85
Analysts	Buy
Price Target	35.25 (+140.12%)
Earnings Date	Feb 18, 2025

About BCYC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 284
• Stock Exchange: NASDAQ
• Ticker Symbol: BCYC
• Website: https://www.bicycletherapeutics.com

Financial Performance

In 2023, Bicycle Therapeutics's revenue was $26.98 million, an increase of 86.52% compared to the previous year's $14.46 million. Losses were -$180.66 million, 60.3% more than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is $35.25, which is an increase of 140.12% from the latest price.

Price Target

$35.25

(140.12% upside)

Analyst Consensus: Buy